ArticleBMC nephrology2026
Analysis of changes in glomerular lesions in children diagnosed with IgA nephropathy following immunosuppressive therapy.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe European STOP study showed that glucocorticoids (with/without immunosuppressants) did not delay disease progression in adults with IgA nephropathy (IgAN). However, pediatric IgAN is characterized by more severe acute inflammatory lesions and milder chronic injuries. This study aimed to evaluate the effects of glucocorticoid‑based immunosuppressive therapy in children with IgAN using paired renal biopsy data.
methodsA retrospective analysis was performed in 36 pediatric IgAN patients who underwent repeat renal biopsies. Patients were stratified by initial crescent status: Group A (no crescents, n = 14) and Group B (cellular/cellular‑fibrous crescents, n = 22). Clinical and pathological changes before and after immunosuppressive therapy were analyzed. MEST‑C scores (semi‑quantitative ordinal variables) were analyzed using the Wilcoxon signed‑rank test. Multiple comparisons were not adjusted due to the exploratory design.
resultsNo significant changes were observed in blood pressure, eGFR, hemoglobin, uric acid, or urinary red blood cell count in either group. Group A showed no significant changes in IgA/C3 deposition or M/E/S/T/C scores. In Group B, serum albumin was significantly increased, and cholesterol and 24‑hour urinary protein were significantly decreased (all p < 0.05). C3 immunofluorescence intensity and E/T/C pathological scores were significantly reduced (all p < 0.05). At repeat biopsy, 16/22 patients in Group B had no residual crescents. Global glomerulosclerosis, focal segmental sclerosis, and capillary loop adhesion remained unchanged in both groups.
conclusionIn children with IgAN, immunosuppressive therapy significantly alleviates proteinuria and reverses acute glomerular lesions including crescents and endothelial hypercellularity. However, eGFR, hematuria, and blood pressure were not significantly improved, suggesting that beneficial effects are mainly confined to proteinuria and acute histological remission, without proven long‑term renal protection. Established chronic lesions are not reversible. This study is limited by a small single‑center sample, selection bias from repeat biopsy indications, and lack of randomization or a control group; findings may not be generalizable to the overall pediatric IgAN population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.